Daily price updates
What planify offer?
Join our channel partner program
Research Reports Related to "Pharmeasy"
Videos Related to "Pharmeasy"
Shorts Related to "Pharmeasy"
Feed Related to "Pharmeasy"
Goldman Sachs is in advanced talks to invest about $350 million (Rs. 2,700 crores) in API Holdings Ltd., the parent of online pharmacy PharmEasy, in a structured debt transaction.
The debt will carry an interest rate of 14-15% and also have a pre-agreed equity upside, or a premium to the rate based on potential increase in the company's valuation. The money will predominantly be used to refinance the debt the company had taken to fund its acquisition of diagnostic chain Thyrocare last year.
Traders' Body Confederation of All India Traders (CAIT) has written to the Security and Exchange Board of India (SEBI) urging the market regulator to dismiss the IPO proposition of e-pharmacy company PharmEasy. CAIT has reasoned that the sale of medicines over the internet is not allowed according to an order passed by the Delhi High Court in 2018. CAIT has alleged that the business model of PharmEasy is "entirely based on gross illegality". The traders' body has pointed out many discrepancies in the DRHP (draft red herring prospectus) of API Holdings, the parent firm of PharmEasy.